SMT202500400T1 - Trattamento della dmle usando una variante di aav2 con aflibercept - Google Patents

Trattamento della dmle usando una variante di aav2 con aflibercept

Info

Publication number
SMT202500400T1
SMT202500400T1 SM20250400T SMT202500400T SMT202500400T1 SM T202500400 T1 SMT202500400 T1 SM T202500400T1 SM 20250400 T SM20250400 T SM 20250400T SM T202500400 T SMT202500400 T SM T202500400T SM T202500400 T1 SMT202500400 T1 SM T202500400T1
Authority
SM
San Marino
Prior art keywords
aflibercept
amd
treatment
aav2 variant
aav2
Prior art date
Application number
SM20250400T
Other languages
English (en)
Italian (it)
Inventor
Mehdi Gasmi
Mark Blumenkranz
Original Assignee
Adverum Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverum Biotechnologies Inc filed Critical Adverum Biotechnologies Inc
Publication of SMT202500400T1 publication Critical patent/SMT202500400T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
SM20250400T 2016-06-16 2017-06-16 Trattamento della dmle usando una variante di aav2 con aflibercept SMT202500400T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351234P 2016-06-16 2016-06-16
EP20196657.9A EP3795181B1 (en) 2016-06-16 2017-06-16 Treatment of amd using aav2 variant with aflibercept

Publications (1)

Publication Number Publication Date
SMT202500400T1 true SMT202500400T1 (it) 2025-11-10

Family

ID=60663653

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20250400T SMT202500400T1 (it) 2016-06-16 2017-06-16 Trattamento della dmle usando una variante di aav2 con aflibercept
SM20210010T SMT202100010T1 (it) 2016-06-16 2017-06-16 Trattamento della amd usando una variante aav2 con aflibercept

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM20210010T SMT202100010T1 (it) 2016-06-16 2017-06-16 Trattamento della amd usando una variante aav2 con aflibercept

Country Status (25)

Country Link
US (2) US20190151409A1 (https=)
EP (3) EP3795181B1 (https=)
JP (5) JP6814822B2 (https=)
KR (2) KR102218265B1 (https=)
CN (2) CN117531025A (https=)
AU (3) AU2017286673B2 (https=)
BR (1) BR112018076124A2 (https=)
CA (1) CA3027737A1 (https=)
CY (1) CY1123697T1 (https=)
DK (2) DK3471780T3 (https=)
ES (2) ES2840059T3 (https=)
FI (1) FI3795181T3 (https=)
HR (2) HRP20251248T1 (https=)
HU (1) HUE051953T2 (https=)
IL (3) IL279919B2 (https=)
LT (2) LT3471780T (https=)
MX (2) MX391779B (https=)
PL (1) PL3795181T3 (https=)
PT (2) PT3471780T (https=)
RS (2) RS61311B1 (https=)
SG (1) SG11201811232XA (https=)
SI (2) SI3795181T1 (https=)
SM (2) SMT202500400T1 (https=)
WO (1) WO2017218974A2 (https=)
ZA (1) ZA201808538B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102537394B1 (ko) 2014-03-17 2023-05-30 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
DK3471780T3 (da) * 2016-06-16 2020-11-23 Adverum Biotechnologies Inc Behandling af amd med aav2-variant med aflibercept
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
CN110546257B (zh) 2017-03-17 2024-03-01 阿德夫拉姆生物技术股份有限公司 用于增强基因表达的组合物和方法
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
DK3717636T5 (da) * 2017-11-27 2024-08-26 4D Molecular Therapeutics Inc Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese
MX2020006435A (es) 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
WO2019198084A1 (en) * 2018-04-12 2019-10-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-aging compositions and methods of use
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
WO2020180951A1 (en) * 2019-03-04 2020-09-10 Adverum Biotechnologies, Inc. Sequential intravitreal administration of aav gene therapy to contralateral eyes
KR20220012231A (ko) * 2019-04-24 2022-02-03 리젠엑스바이오 인크. 완전-인간 번역 후 변형된 항체 치료제
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
FI4027983T3 (fi) * 2019-09-11 2026-02-03 Adverum Biotechnologies Inc Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla
AU2019465527A1 (en) * 2019-09-11 2022-03-10 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using AAV2 variants encoding aflibercept
US11400039B2 (en) 2020-01-16 2022-08-02 James W. Hill Changing eye color by gene transduction
FR3111913A1 (fr) * 2020-06-30 2021-12-31 Eyevensys Construction d’adn pour le traitement de pathologies oculaires
CN113952473A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
JP7842082B2 (ja) * 2020-07-21 2026-04-07 エフティージェン コーポレーション 眼疾患を処置するための組成物および方法
CN113952474A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
CN113817775B (zh) * 2020-08-25 2023-02-17 南京吉迈生物技术有限公司 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用
BR112023003548A2 (pt) * 2020-09-03 2023-04-04 Univ Massachusetts Vírus adenoassociado para liberação de kh902 (conbercept) e usos do mesmo
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
JP2021049374A (ja) * 2020-12-09 2021-04-01 株式会社三洋物産 遊技機
JP2024515459A (ja) * 2021-04-27 2024-04-10 アドヴェラム バイオテクノロジーズ， インコーポレイテッド アフリベルセプトをコードするａａｖ２バリアントを使用する眼疾患の治療方法
CN118660913A (zh) 2022-02-21 2024-09-17 上海瑞宏迪医药有限公司 Vegf结合分子及其医药用途
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025040166A1 (zh) 2023-08-23 2025-02-27 上海瑞宏迪医药有限公司 药物组合物及其用途
WO2025072688A2 (en) * 2023-09-27 2025-04-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adeno-associated virus vectors for nucleic acid delivery to retinal cells, for nucleic acid delivery across retinal regions, or for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells
WO2025073297A1 (zh) * 2023-10-06 2025-04-10 甘李药业股份有限公司 表达抗vegf融合蛋白的aav病毒载体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171334T1 (hr) * 2011-04-22 2017-11-17 The Regents Of The University Of California Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe
HUE046134T2 (hu) * 2012-05-07 2020-02-28 Allergan Inc Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
TWI775096B (zh) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US20150111275A1 (en) * 2012-06-11 2015-04-23 Daniel V. Palanker Optical regulation of gene expression in the retina
AU2014286996A1 (en) * 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
WO2015058048A1 (en) * 2013-10-18 2015-04-23 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
DK3471780T3 (da) * 2016-06-16 2020-11-23 Adverum Biotechnologies Inc Behandling af amd med aav2-variant med aflibercept

Also Published As

Publication number Publication date
JP2020203941A (ja) 2020-12-24
SG11201811232XA (en) 2019-01-30
ES3049818T3 (en) 2025-12-18
SMT202100010T1 (it) 2021-03-15
MX2022004786A (es) 2022-05-16
CY1123697T1 (el) 2022-03-24
HRP20201842T1 (hr) 2021-04-16
KR20210021113A (ko) 2021-02-24
IL314568B2 (en) 2025-09-01
WO2017218974A3 (en) 2018-01-25
IL279919A (en) 2021-03-01
JP2022137244A (ja) 2022-09-21
JP2019521990A (ja) 2019-08-08
CA3027737A1 (en) 2017-12-21
FI3795181T3 (fi) 2025-10-14
AU2017286673A1 (en) 2019-01-31
BR112018076124A2 (pt) 2019-03-26
JP2025186377A (ja) 2025-12-23
HRP20251248T1 (hr) 2026-01-16
IL279919B2 (en) 2025-01-01
SI3795181T1 (sl) 2025-11-28
EP3471780A4 (en) 2019-04-24
AU2025202930A1 (en) 2025-05-15
DK3471780T3 (da) 2020-11-23
US20220265740A1 (en) 2022-08-25
EP4671369A2 (en) 2025-12-31
ZA201808538B (en) 2021-04-28
IL279919B1 (en) 2024-09-01
SI3471780T1 (sl) 2021-03-31
JP6814822B2 (ja) 2021-01-20
MX2018015512A (es) 2019-04-24
DK3795181T3 (da) 2025-10-13
IL314568A (en) 2024-09-01
EP3471780B1 (en) 2020-10-28
EP3795181B1 (en) 2025-08-06
EP3795181A1 (en) 2021-03-24
EP3471780A2 (en) 2019-04-24
CN117531025A (zh) 2024-02-09
JP2024113193A (ja) 2024-08-21
KR102218265B1 (ko) 2021-02-25
PT3471780T (pt) 2020-12-17
AU2021225178B2 (en) 2025-01-30
CN109641065A (zh) 2019-04-16
WO2017218974A2 (en) 2017-12-21
HUE051953T2 (hu) 2021-04-28
PT3795181T (pt) 2025-11-05
IL263686A (en) 2019-01-31
LT3471780T (lt) 2021-01-25
IL263686B (en) 2021-02-28
ES2840059T3 (es) 2021-07-06
RS67328B1 (sr) 2025-11-28
KR20190037228A (ko) 2019-04-05
AU2021225178A1 (en) 2021-09-30
EP4671369A3 (en) 2026-03-18
AU2017286673B2 (en) 2021-06-24
PL3795181T3 (pl) 2025-12-22
IL314568B1 (en) 2025-05-01
RS61311B1 (sr) 2021-02-26
US20190151409A1 (en) 2019-05-23
LT3795181T (lt) 2025-12-29
MX391779B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
ZA201808538B (en) Treatment of amd using aav2 variant with aflibercept
ZA202006746B (en) Methods of treatment
ZA201803727B (en) Treatment of fibrosis
IL274865A (en) Treatment methods with asparaginase
IL258002A (en) Cenicriviroc combination therapy for the treatment of fibrosis
IL250960A0 (en) Combined treatment of sinecriviroc for the treatment of leprosy
IL247515A0 (en) Snekribirock for the treatment of leprosy
ZA201705847B (en) Treatment of pain
IL253617A0 (en) Snekribirock for the treatment of leprosy
GB201614415D0 (en) Enzymes for the treatment of human enterometabolic dysfunction
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
ZA201608406B (en) Enzyme treatment composition
ZA201608775B (en) Hair treatment composition
GB201512139D0 (en) Methods of treatment
GB201407806D0 (en) Treatment of fibrosis
ZA201608404B (en) Enzyme treatment composition
GB201607972D0 (en) Hair treatment composition
GB201418268D0 (en) Composition & methods of treatment